TScan Therapeutics Director Acquires 18% More Stock

Whilst it may not be a huge deal, we thought it was good to see that the TScan Therapeutics, Inc. (NASDAQ:TCRX) Director, Barbara Klencke, recently bought US$56k worth of stock, for US$5.61 per share. While we're hesitant to get too excited about a purchase of that size, we do note it increased their holding by a solid 18%.

Check out our latest analysis for TScan Therapeutics

The Last 12 Months Of Insider Transactions At TScan Therapeutics

Over the last year, we can see that the biggest insider purchase was by insider Timothy Barberich for US$142k worth of shares, at about US$4.97 per share. Even though the purchase was made at a significantly lower price than the recent price (US$5.69), we still think insider buying is a positive. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.

Happily, we note that in the last year insiders paid US$224k for 44.15k shares. On the other hand they divested 7.50k shares, for US$43k. In the last twelve months there was more buying than selling by TScan Therapeutics insiders. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.

Insider Ownership

For a common shareholder, it is worth checking how many shares are held by company insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. From looking at our data, insiders own US$2.3m worth of TScan Therapeutics stock, about 0.8% of the company. However, it's possible that insiders might have an indirect interest through a more complex structure. We consider this fairly low insider ownership.

So What Do The TScan Therapeutics Insider Transactions Indicate?

Our data shows a little insider buying, but no selling, in the last three months. Overall the buying isn't worth writing home about. But insiders have shown more of an appetite for the stock, over the last year. We'd like to see bigger individual holdings. However, we don't see anything to make us think TScan Therapeutics insiders are doubting the company. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. At Simply Wall St, we found 2 warning signs for TScan Therapeutics that deserve your attention before buying any shares.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.